EndoPredict

EndoPredict is a prognostic test for women with early-stage, ER+, HER2− primary breast cancer.

EndoPredict helps to define the risk of breast cancer recurrence, the benefits of chemotherapy, and who can benefit from extended endocrine therapy. EndoPredict is for post- and premenopausal women with early (non-metastatic) ER+, HER2- breast cancer, with or without affected lymph nodes. It is available locally in Australia through Clinical Labs and now features a partial Medicare rebate.

How do I know if EndoPredict is suitable for me?

After learning that you have breast cancer, it can be challenging to understand all your options for testing and treatment. Using your first biopsy, the amount of protein made by different genes was checked. These genes were:

Estrogen receptor (ER)
Progesterone receptor (PR)
Human epidermal growth factor receptor 2 (HER2)

Knowing whether your tumour makes these proteins, along with additional testing like EndoPredict, can help your doctor determine the best treatment for your breast cancer.

How does EndoPredict help me understand the risk of breast cancer recurrence?

The EndoPredict test results provide details about your specific breast cancer, including the risk of your cancer returning in the 10 years after treatment if you do not have chemotherapy. Your results will clearly note whether you are LOW risk or HIGH risk.

A low-risk result means that if you do not have chemotherapy, the risk of your cancer returning within 10 years is LOW.
A high-risk result means that if you do not have chemotherapy, the risk of your cancer returning is HIGH.

How does EndoPredict help determine whether chemotherapy is right for me?

EndoPredict shows your individual risk of your breast cancer returning in the next 10 years if you were treated by hormone therapy alone. It also estimates how much chemotherapy is likely to reduce the risk of your breast cancer returning.

How does EndoPredict help identify whether extended hormone therapy should be considered?

EndoPredict shows your risk of your breast cancer returning in the 10 years after you received 5 years of hormone therapy. This can help you and your doctor to decide if 5 years of hormone therapy is enough or if extended hormone therapy should be considered.

Creating a treatment plan that’s right for you

After surgery, you will make treatment choices with the goal of lowering the chance that your cancer will return, or recur, in the future. For patients who have ER+ breast cancer, endocrine therapy is standard or routine. It can lower the risk of the cancer returning—also called the risk of recurrence—by almost half. Some patients will receive both endocrine therapy and chemotherapy. Your doctor will weigh several factors to decide if adding chemotherapy would benefit you further.

For patients who have a long-term risk of recurrence that is LOW, adding chemotherapy is unlikely to improve the absolute benefit by much.
For patients who have a long-term risk of recurrence that is HIGH, adding chemotherapy may help significantly lower the risk.

EndoPredict helps guide important treatment decisions for your cancer journey, making it possible to personalise your treatment.